ECCO 2026

Nordic Bioscience’s gastroenterology team will be attending ECCO 2026, held February 18–21, 2026, in Stockholm, Sweden. As one of the most influential congresses in inflammatory bowel disease, ECCO provides a focused setting for scientific exchange across clinical practice, translational research, and drug development.

At this year’s meeting, we will be exhibiting and highlighting CPa9-HNE™, our serum-based calprotectin biomarker designed to measure true neutrophil activity. By capturing a specific fragment generated during neutrophil activation, CPa9-HNE offers a non-invasive and dynamic readout of intestinal inflammation, with clear relevance for disease monitoring, patient stratification, and assessment of treatment response in IBD. More details on the technology can be found here.

Visit us at Booth 38 to discuss how CPa9-HNE and our broader biomarker portfolio can support IBD research and clinical programs.

Unlike traditional calprotectin assays, CPa9-HNE provides a more precise readout of active inflammation, offering valuable insight into disease activity and treatment response in conditions such as inflammatory bowel disease. Backed by FDA support for further clinical application, this biomarker is being integrated into clinical trials to improve patient selection and reduce reliance on invasive procedures.